High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma (original) (raw)

• Liotta LA, Rao CN, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest 1983; 49: 636–49.
  PubMed CAS Google Scholar
• Werb Z. ECM and cell surface proteolysis: Regulating cellular ecology. Cell 1997; 91: 439–42.
  Article PubMed CAS Google Scholar
• Crawford HC, Matrisian LN. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 1994-5; 14: 234–45.
  PubMed CAS Google Scholar
• Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993; 71: 1368–83.
  Article PubMed CAS Google Scholar
• Matrisian LM. The matrix-degrading metalloproteinases. Bioessays 1992; 14: 455–63.
  Article PubMed CAS Google Scholar
• Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: An imbalance of positive and negative regulation. Cancer Res 1991; 51: 5054s–5059s (suppl).
  PubMed CAS Google Scholar
• Tryggvason K, Höyhtyä M, Pyke C. Type IV collagenases in invasive tumors. Breast Cancer Res Treat 1993; 24: 209–18.
  Article PubMed CAS Google Scholar
• Stetler-Stevenson WG, Liotta LA, Kleiner DE, Jr. Extracellular matrix6: Role of matrix metalloproteinases in tumor invasion and metastasis. Faseb J 1993; 7: 1434–41.
  PubMed CAS Google Scholar
• Woessner JF, Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. Faseb J 1991; 5: 2145–54.
  PubMed CAS Google Scholar
• Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260–70.
  Article PubMed CAS Google Scholar
• Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996; 65: 5–27.
  Google Scholar
• Petterson F. International Federation of Gynecology and Obstetrics: Annual report on the results of treatment in gynecological cancer. Stockholm: Panorama Press AB 1995; 83-102, 201–227
  Google Scholar
• Hoskins WJ. Prospective on ovarian cancer: Why prevent? J Cell Biochem 1995; 23: 189–99.
  Article CAS Google Scholar
• Ellerbroek SM, Hudson LG, Stack MS. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion. Int J Cancer 1998; 78: 331–37.
  Article PubMed CAS Google Scholar
• Westerlund A, Hujanen E, Puistola U, Turpeenniemi-Hujanen T. Fibroblasts stimulate human ovarian cancer cell invasion and expression of 72-kDa Gelatinase A (MMP-2). Gynecol Oncol 1997; 67: 76–82.
  Article PubMed CAS Google Scholar
• Moore DH, Allison B, Look KY et al. Collagenase expression in ovarian cancer cell lines. Gynecol Oncol 1997; 65: 78–82.
  Article PubMed CAS Google Scholar
• Boyd RS, Balkwill FR. MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts. Br J cancer 1999; 80: 315–21.
  Article PubMed CAS Google Scholar
• Höyhtyä M, Fridman R, Komarek D et al. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 1994; 56: 500–5.
  PubMed Google Scholar
• Takemura M, Azuma C, Kimura T et al. Type-IV collagenase and tissue inhibitor of metalloproteinase in ovarian cancer tissues. Int J Gynecol Obstet 1994; 46: 303–9.
  Article CAS Google Scholar
• Afzal S, Lalani EN, Poulsom R et al. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors. Possible implications for the role of desmoplastic fibroblasts. Hum Pathol 1998; 29: 155–65.
  Article PubMed CAS Google Scholar
• Afzal S, Lalani EN, Foulkes WD et al. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest 1996; 74: 406–21.
  PubMed CAS Google Scholar
• Fishman DA, Bafetti LM, Banionis S et al. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer 1997; 80: 1457–63.
  Article PubMed CAS Google Scholar
• Young TN, Rodriguez GC, Rinehart AR et al. Characterization of Gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: Purification of matrix metalloproteinase 2. Gynecol Oncol 1996; 62: 89–99.
  Article PubMed CAS Google Scholar
• Fishman DA, Bafetti LM, Stack MS. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis 1996; 16: 150–9.
  PubMed CAS Google Scholar
• Naylor MS, Stamp GW, Davies BD, Balkwill FR. Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 1994; 58: 50–6.
  PubMed CAS Google Scholar
• Campo E, Merino MJ, Tavassoli FA et al. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol 1992; 16: 500–7.
  PubMed CAS Google Scholar
• Autio-Harmainen H, Karttunen T, Hurskainen T. et al. Expression of 72 kilodalton type IV collagenase (Gelatinase A) in benign and malignant ovarian tumors. Lab Invest 1993; 69: 312–21.
  PubMed CAS Google Scholar
• Stack MS, Ellerbroek SM, Fishman DA. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma (review). Int J Oncol 1998; 12: 569–76.
  PubMed CAS Google Scholar
• De Nictolis M, Garbisa S, Lucarini G, et al. 72-KiloDalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors of the ovary: A clinicopathologic, immunohistochemical, and serological study. Int J Gynecol Pathol 1996; 15: 102–9.
  Article PubMed CAS Google Scholar
• Garzetti GG, Ciavattini A, Lucarini G et al. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystadenocarcinomas: Clinical and prognostic implications. Anticancer Res 1995; 15: 2799–804.
  PubMed CAS Google Scholar
• Westerlund A, Apaja-Sarkkinen M Höyhtyä M et al. Gelatinase A-immunoreactive protein in ovarian lesions-prognostic value in epithelial ovarian cancer. Gynecol Oncol 1999; 75: 91–8.
  Article PubMed CAS Google Scholar
• Zaloudek C. Ovarian neoplasms. In Gompel C, Silverberg SG (eds): Pathology in Gynecology and Obstetrics. Philadelphia: Lippincott 1994; 330–402.
  Google Scholar
• Rosai J. Ackerman's Surgical Pathology. St. Louis: Mosby 1996; 1492–3.
  Google Scholar
• Parks CS, Brigati DJ, Manahan LJ. Automated molecular pathology: one-hour in-situ DNA hybridization. J Histotechnol 1991; 14: 219–29.
  Google Scholar
• Reed JA, Manahan LJ, Parks CS, Brigati DJ. Complete one-hour immunocytochemistry based on capillary action. Biotechniques 1992; 13: 434–43.
  PubMed CAS Google Scholar
• Greene GF, Kitadai Y, Pettaway CA et al. Correlation of metastasisrelated gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol 1997; 150: 1571–82.
  PubMed CAS Google Scholar
• Davidson B, Goldberg I, Kopolovic J et al. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma-A clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 1999; 73: 372–82.
  Article PubMed CAS Google Scholar
• Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999; 43: S42–S51 (Suppl).
  Article PubMed CAS Google Scholar
• Macaulay VM, O'Bryne KJ, Saunders MP et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 1999; 5: 513–20.
  PubMed CAS Google Scholar
• Ferrante K, Winograd B, Canetta R. Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 1999; 43: S61–S68 (Suppl).
  Article PubMed CAS Google Scholar
• Yamamoto H, Itoh F, Adachi Y et al. Messenger RNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human hepatocellular carcinoma. Jpn J Clin Oncol 1999; 29: 58–62.
  Article PubMed CAS Google Scholar
• Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996; 14: 3133–40.
  PubMed CAS Google Scholar
• Miyajima Y, Nakano R, Morimatsu M. Analysis of expression of matrix metalloproteinases-2 and-9 in hypopharyngeal squamous cell carcinoma by in situ hybridization. Ann Otol Rhinol Laryngol 1995; 104: 678–84.
  PubMed CAS Google Scholar
• Nuovo GJ, MacConnel PB, Simsir A et al. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 1995; 55: 267–75.
  PubMed CAS Google Scholar
• Pacheco MM, Mourao M, Mantovani EB et al. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis 1998; 16: 577–85.
  Article PubMed CAS Google Scholar
• Ree AH, Florenes VA, Berg JP et al. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 1997; 3: 1623–28.
  PubMed CAS Google Scholar
• Kuniyasu H, Ellis LM, Evans DB et al. Relative expression of Ecadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin Cancer Res 1999; 5: 25–33.
  PubMed CAS Google Scholar
• Caenazzo C, Onisto M, Sartor L et al. Augmented membrane type 1 matrix metalloproteinase (MT1-MMP):MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis. Clin Cancer Res 1998; 4: 2179–86.
  PubMed CAS Google Scholar
• Sier CF, Kubben FJ, Ganesh S et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996; 74: 413–7.
  PubMed CAS Google Scholar
• Kanayama H, Yokota K, Kurokawa Y et al. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 1998; 82: 1359–66.
  Article PubMed CAS Google Scholar
• Wood M, Fudge K, Mohler JL et al. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997; 15: 246–58.
  Article PubMed CAS Google Scholar
• Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: An analysis of 1973-1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994; 10: 31–46.
  PubMed CAS Google Scholar
• Grignon DJ, Sakr W, Toth M et al. High levels of tissue inhibitor of metalloproterinase-2 (TIMP-2) are associated with poor outcome in invasive bladder cancer. Cancer Res 1996; 56: 1654–9.
  Google Scholar
• Fishman DA, Kearns A, Chilukuri K et al. Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2beta1-integrin-mediated interaction with type I collagen. Invasion Metastasis 1998; 18: 15–26.
  Article PubMed CAS Google Scholar
• Ellerbroek SM, Fishman DA, Kearns A et al. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. Cancer Res 1999; 59: 1635–41.
  PubMed CAS Google Scholar